Jack Chen
Director - Scientific Translational Oncology, Precision Medicine Abbvie
Jack Chen is Scientific Director of Translational Oncology, Precision Medicine at AbbVie, where he leads efforts to integrate biomarker strategies into oncology drug development, with a particular focus on ADCs and immuno‑oncology programs. He oversees cross‑functional teams driving translational research from preclinical discovery through early clinical studies. Jack brings over a decade of biopharma experience, including leadership roles at Pfizer, OncoMed, and Eli Lilly in cancer biology and immunotherapy. He holds a PhD from Johns Hopkins University and combines deep scientific expertise with a strong focus on precision medicine to advance targeted cancer treatments.
Seminars
- Prioritizing biomarker and patient selection approaches to reflect a maturing ADC clinical development pipeline
- Highlighting biomarker development to identify patients with the most sensitive ADC response
- Utilizing reverse translation approaches to understand mechanisms behind clinical success to apply to ongoing ADC translational studies
